Crinetics Pharmaceuticals gains FDA approval for PALSONIFY, targeting key unmet needs in Acromegaly. Click here to read my ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

Researchers reviewed current evidence on the chaya plant (Cnidoscolus chayamansa), highlighting its nutritional profile, ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

Viridian Therapeutics (VRDN) offers a differentiated next-gen therapy for Thyroid Eye Disease, targeting a large, underpenetrated market dominated ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Want to live to 100? Well, here’s some news that might make your pizza-loving heart skip a beat (and not in a good way).

The discovery of this petite primate in 2004 sent palaeontologists into a bit of a spin, as the species breaks one of the ...

The Member of Parliament for North Tongu, Samuel Okudzeto Ablakwa, in October 2024, exposed a US$38.2 million visa processing ...